CSBio CSBio

X
[{"orgOrder":0,"company":"Cardior Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cardior Pharmaceuticals Demonstrates Reversal of Heart Failure with Lead Compound CDR132L","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I","country":"GERMANY","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"January 2020","url1":"","url2":"","graph1":"Undisclosed","graph2":"Cardior Pharmaceuticals"},{"orgOrder":0,"company":"Cardior Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cardior Pharmaceuticals' CDR132 Demonstrates Improvement of Heart Function in Chronic Heart Failure Model","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I","country":"GERMANY","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Cardior Pharmaceuticals"},{"orgOrder":0,"company":"Cardior Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Independent Peer-Reviewed Study Validates Therapeutic Mode of Action of Cardior's First-in-Class Heart Failure Program","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I","country":"GERMANY","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2021","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Cardior Pharmaceuticals"},{"orgOrder":0,"company":"Cardior Pharmaceuticals","sponsor":"Inkef Capital","pharmaFlowCategory":"D","amount":"$76.0 million","upfrontCash":"Undisclosed","newsHeadline":"Cardior Raises \u20ac64 M Series B to Advance Clinical Pipeline of RNA Therapeutics to Treat Cardiac Disease","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I","country":"GERMANY","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Cardior Pharmaceuticals"},{"orgOrder":0,"company":"Phenex Pharmaceuticals","sponsor":"OrsoBio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"OrsoBio Announces Acquisition of LXR Inverse Agonist Program for Treatment of Severe Dyslipidemias from Phenex Pharmaceuticals","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I","country":"GERMANY","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Phenex Pharmaceuticals"}]

Find Drugs for Cardiology/Vascular Diseases in Phase I Clinical Development in GERMANY

Loading...
Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Details:

            TLC-2716 is a liver-targeted, inverse agonist of LXR that regulates plasma triglycerides and cholesterol via multiple mechanisms, including inhibition of DNL, increased clearance of triglyceride- and cholesterol-rich lipoproteins, and reduced intestinal lipid absorption.

            Lead Product(s): TLC-2716

            Therapeutic Area: Cardiology/Vascular Diseases Product Name: TLC-2716

            Highest Development Status: Phase I Product Type: Small molecule

            Partner/Sponsor/Collaborator: OrsoBio

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Acquisition November 02, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The Series B proceeds will be used to fund the late-stage clinical development of Cardior’s lead program, CDR132L and the expansion of the company’s earlier-stage pipeline.

            Lead Product(s): CDR132L

            Therapeutic Area: Cardiology/Vascular Diseases Product Name: CDR132L

            Highest Development Status: Phase I Product Type: Large molecule

            Partner/Sponsor/Collaborator: Inkef Capital

            Deal Size: $76.0 million Upfront Cash: Undisclosed

            Deal Type: Series B Financing August 25, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The recent peer-reviewed study confirms the therapeutic mode of action of Cardior´s lead program CDR132L. CDR132L blocks the naturally occurring microRNA miR-132 which, if overexpressed, is a key driver of heart failure.

            Lead Product(s): CDR132L

            Therapeutic Area: Cardiology/Vascular Diseases Product Name: CDR132L

            Highest Development Status: Phase I Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 29, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The study demonstrates that repeated treatment with its lead compound Cdr132 L is safe, improves cardiac function and reduces both ventricular as well as left atrial volumes in chronic heart failure.

            Lead Product(s): CDR132L

            Therapeutic Area: Cardiology/Vascular Diseases Product Name: CDR132L

            Highest Development Status: Phase I Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 22, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            In the in vivo study, Cardior´s compound CDR132L effectively prevented maladaptive growth and remodeling and restored cardiac function in a dose-dependent manner.

            Lead Product(s): CDR132L

            Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed

            Highest Development Status: Phase I Product Type: Undisclosed

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 31, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY